Positive interim data for Ixaka’s lead ‘multi-cell’ therapy
The independent data monitoring committee (DMC) has recommended continuation of the Phase III trial
Read More
Tag: UK Biotech
Exonate launches diabetic macular oedema trial
Study of lead asset is part of a collaboration with Janssen Pharmaceuticals
Read More
UK biotech Ixaka scores additional funding for cell and gene therapy research
Lead asset REX-001 is in Phase III development for chronic limb-threatening ischaemia
Read More
Scancell picks lead COVID-19 vaccine candidate
SN14 will be advanced through further development and clinical trials
Read More
UK Biotech still going strong at the start of 2019
The UK Biotech industry is showing a strong outlook at the start of 2019, despite the uncertainties of Brexit.
Read More
- Myomaker Bio unveils lab‑grown human muscle platform to transform drug testing
- Survodutide delivers 16.6% weight loss in major phase 3 obesity trial
- Kahimmune Therapeutics signs collaboration agreement with Gustave Roussy
- BioDuro and CTI Biotechnology form partnership to accelerate preclinical drug development
- Asgard Therapeutics to present new preclinical data on AT‑108 at ASGCT 2026
